Stock Analysis·← Pickers

DWTX

Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. (DWTX) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 44.7, with 0/3 trend checks passing.

Price
$1.44
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
44.7
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

DWTX with MA50 and MA200

7.916.274.632.981.3407/3110/2401/2204/1707/15
DWTX2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$1.60-9.79% vs price
MA200
$3.47-58.52% vs price
RSI (14)
44.7Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for DWTX

Dogwood Therapeutics, Inc. (DWTX) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $1.44, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 9.8% and below the 200-day moving average by 58.5%.

Momentum and stretch context

DWTX currently has an RSI reading of 44.7, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing DWTX next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

Sector
Healthcare
Industry
Biotechnology
CEO
Gregory Duncan
Employees
8
Market cap
$2.8M
Beta
1.71
52-week range
$1.28 – $9.50
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
17 Dec 2020
ISIN
US92829J2033
CUSIP
92829J203
Website
dwtx.com
Company profile data from Financial Modeling Prep. DWTX listed on NASDAQ.
Share dilution

DWTX shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
33.5M
Since Jun 2019
+17253.8%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. DWTX28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about DWTX

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.